

# ACCRELIST LTD. (亚联盛控股公司)

(Company Registration No. 198600445D)  
(Incorporated in the Republic of Singapore)

---

## PROPOSED INTERNAL RESTRUCTURING OF SUBSIDIARIES WITHIN THE GROUP'S MEDICAL AESTHETIC BUSINESS

---

### 1. INTRODUCTION

The Board of Directors (the “**Board**”) of the Accrelist Ltd. (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) wishes to announce that the Company has arranged for an internal restructuring that will result in the Company’s wholly-owned subsidiary, Accrelist Medical Aesthetics (BM) Pte. Ltd. (“**BM**”) transferring its entire 95% shareholding interest in the Company’s indirect subsidiary incorporated in the People’s Republic of China, Accrelist Medical Aesthetics (Hainan) Co, Ltd. (“**AM Hainan**”) to BM’s wholly-owned subsidiary, Accrelist Medical Aesthetics (China) Pte. Ltd. (“**AM China**”), via a share swap agreement for additional shares in AM China (“**BM Restructuring**”).

### 2. BM RESTRUCTURING

BM and AM China, has on 27 March 2024, entered into a conditional sale and purchase agreement (“**SPA**”) to transfer shares of AM Hainan to AM China, in exchange for AM China shares based on the net asset value as at 30 September 2023.

The transfer from BM to AM China is conditional upon first satisfying the condition precedent that the transfer of AM Hainan shares has been approved by the Hainan Administration for Market Regulation.

The time of completion of the transfer shall be determined by the SPA parties.

### 3. CONSIDERATION

BM shall transfer its 95% shareholding interest in AM Hainan to AM China in exchange for 10,556 of AM China shares at the time of completion.


### 4. RATIONALE OF BM RESTRUCTURING

The intended effect of the BM Restructuring is to streamline the Group’s Medical Aesthetics structure by consolidating all of the Group’s Medical Aesthetic business that operates within, or is related to business conducted in the People’s Republic of China.


### 5. ORGANISATION STRUCTURE

Graphical representations of the Group’s corporate structure limited only to the Group’s Medical Aesthetics companies, before and after the completion the BM Restructuring, are provided below:

## Before BM Restructuring



## After BM Restructuring



## 6. INTERESTS OF DIRECTORS AND CONTROLLING SHAREHOLDERS

As at the date of this announcement, none of the Directors or controlling shareholders of the Company has any interest, direct or indirect, in the BM Restructuring, other than through their respective shareholding interest, direct or indirect, in the Company.

## 7. FURTHER ANNOUNCEMENT

The Company will make further announcements, as and when necessary, to update its shareholders when there are material developments in relation to the matter above.

## BY ORDER OF THE BOARD

Mr. Terence Tea Yeok Kian  
Executive Chairman & Managing Director  
3 April 2024

---

*This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, RHT Capital Pte. Ltd. ("Sponsor"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited ("SGX-ST").*

*This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Mr Joseph Au, Registered Professional, RHT Capital Pte. Ltd., 36 Robinson Road, #10-06 City House, Singapore 068877, [sponsor@rhtgoc.com](mailto:sponsor@rhtgoc.com).*